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Our study shows that the in situ microbial community of the
diseased bowel in patients with Crohn’s disease is distinct
from inﬂammatory bowel disease–free individuals. In
Crohn’s disease patients, the microbial composition at the
phyla level did not differ markedly between healthy and
diseased areas, but at the species level an enrichment of
potentially pathogenic organisms was observed in the
diseased ileum.*Authors share co-ﬁrst authorship.
Abbreviations used in this paper: CD, Crohn’s disease; FDR, false-
discovery rate; IBD, inﬂammatory bowel disease; LDA, linear
discriminant analysis.
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http://dx.doi.org/10.1016/j.jcmgh.2016.05.011BACKGROUND & AIMS: Microbial dysbiosis and aberrant
host–microbe interactions in the gut are believed to contribute
to the development and progression of Crohn’s disease (CD).
Microbiome studies in CD typically have focused on microbiota
in feces or superﬁcial mucosal layers of the colon because
accessing DNA from deeper layers of the bowel is challenging.
In this study, we analyzed the deep tissue microbiome in pa-
tients who underwent surgical resection of the small intestine.
METHODS: Parafﬁn blocks were obtained from 12 CD patients
undergoing ileocecal resection, and healthy ileum samples
(inﬂammatory bowel disease–free controls) were obtained from
12 patients undergoing surgery for right-sided colon cancer.
Diseased and healthy-appearing ileum was identiﬁed using mi-
croscopy, and parafﬁn blocks were macrodissected using a core
needle to speciﬁcally isolate DNA. Illumina Whole Genome
Sequencing was used for microbial sequence identiﬁcation and
subsequent taxonomic classiﬁcation using the PathSeq tool.
RESULTS: We observed signiﬁcant differences between the
microbiome of CD samples vs inﬂammatory bowel disease–free
controls, including depletion of Bacteroidetes and Clostridia.
Notably, microbial composition at the phyla level did not differ
markedly between healthy and diseased areas of CD patients.
However, we observed enrichment of potentially pathogenic
organisms at the species level.
CONCLUSIONS: Our study showed dysbiosis within deeper
layers of the ileum of CD patients, speciﬁcally enrichment of
enterotoxigenic Staphylococcus aureus and an environmental
Mycobacterium species not described previously. Future
studies with larger cohort sizes are warranted to conﬁrm these
ﬁndings. Studies would beneﬁt from effective microbial DNAextraction methods from parafﬁn sections and host nucleic acid
depletion approaches to increase microbial read coverage. (Cell
Mol Gastroenterol Hepatol 2016;2:563–566; http://dx.doi.org/
10.1016/j.jcmgh.2016.05.011)
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icrobial communities in the gut lumen of patientsMwith Crohn’s disease (CD) are distinct from those
observed in healthy controls and include depletion of
commensal phyla such as Firmicutes and Bacteroidetes.1,2
Although the etiology of this dysbiosis is unclear, it is
thought to trigger intestinal inﬂammation.3 Microbiome
studies in CD typically have focused on the microbiota in
feces or in the superﬁcial mucosal layers of the colon
because accessing tissue from the deeper layers of the
bowel is challenging.
To identify potential pathogens we took an in situ
approach to determine invasive tissue microbiota. We
analyzed the deep tissue microbiome in patients who un-
derwent surgical resection of the small intestine. Inﬂamed
(diseased or involved) and uninﬂamed (healthy or unin-
volved) areas of the resection specimens were selected from
the same patient for analysis (Supplementary Table 1). Spe-
ciﬁcally, samples were obtained from 12 patients who un-
derwent ileocecal resections at Massachusetts General
Hospital (Boston, MA) for treatment of Crohn’s disease and
who were part of the Prospective Registry in Inﬂammatory
Bowel Disease (IBD) study at Massachusetts General
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course of the disease (<5 years after diagnosis). Healthy
ileum samples were obtained from patients undergoing a
similar surgery for right-sided colon cancer and were desig-
nated as IBD-free controls. Deeper sections of the small bowel
were macrodissected from these surgical specimens. The
submucosal lymphoid areas, granulomas, and lymphoid re-
actions around ﬁssures were identiﬁed by histologic exami-
nation of the tissue by a pathologist and co-investigator
(A.K.B.). The diseased (involved) areawas identiﬁedand cored
on parafﬁn blocks (Supplementary Figure 1B and C) using a
1.5-mm dermal punch as described previously.4 Punch bi-
opsies were performed using sterilized, disposable needles
and samples were placed directly into sterile Eppendorf tubes
for further processing. Healthy-appearing (uninvolved) ileum
from these CD patients and IBD-free ileum from patients un-
dergoing surgery for right-sided colon cancer were cored
similarly. DNA extraction and preparation of bar-coded DNA
sequencing libraries were performed as previously
described.4 Microbial sequence identiﬁcation and subsequent
taxonomic classiﬁcation was performed using the PathSeq
tool.5
Microbial DNA was identiﬁed in the deeper bowel layers
in all 3 experimental groups: involved (n ¼ 12 samples)
and uninvolved (n ¼ 11 samples; 1 surgical resection did
not contain an uninvolved segment) regions from ileal
segments of 12 CD patients, and IBD-free control (n ¼ 12
samples) ileal segments from 12 right-sided colon cancer
patients. The microbiomes of all 3 groups were dominated
by 4 phyla (Actinobacteria, Firmicutes, Bacteroidetes, and
Proteobacteria). The relative abundance of these phyla,
however, varied between the groups (Figure 1A). Reads
corresponding to viral, archaeal and fungal sequences were
virtually absent (Supplementary Tables 2 and 3). At the
phylum level, the microbial community was similar in
involved and uninvolved regions but differed markedly
from the microbiomes of IBD-free patients (Figure 1A). In
particular, we observed depletion of commensal bacterialA B
Figure 1. (A) Relative abundance of bacterial phyla in involved
Box plots showing relative abundance of Actinobacteria, Bacte
vised hierarchical clustering of bacterial genus level relative abun
green, IBD-free). AU, approximately unbiased; BP, bootstrap prphyla such as Bacteroidetes in the involved and uninvolved
regions compared with IBD-free ileum. The depletion in
Bacteroidetes was especially signiﬁcant (P ¼ .0002;
involved vs IBD-free ileum), with nearly 10-fold greater
relative abundance in IBD-free ileum (10.22% mean rela-
tive abundance, compared with 1.15% and 0.82% mean
relative abundance in involved and uninvolved regions,
respectively). The relative abundance of Firmicutes
conversely was higher in the involved regions vs IBD-free
ileum (P ¼ .0204), whereas abundance of the 2 other
dominant phyla, Actinobacteria (P ¼ .2189) and Proteo-
bacteria (P ¼ .1005), was not signiﬁcantly different in
involved vs IBD-free ileal specimens (Figure 1A). Here, it is
important to note that the CD patients in this study were
prescribed metronidazole and levoﬂoxacin during the
course of their treatment. Metronidazole speciﬁcally tar-
gets anaerobic and microaerophilic bacteria, including
Bacteroidetes and members of the Firmicutes phylum con-
taining the class Clostridia. We therefore cannot rule out
the possibility that antibiotic treatment may have contrib-
uted to the depletion of members of these phyla in patients
with Crohn’s disease. Although all patients were treated
with antibiotics, the duration of treatment varied. We
decided to compare longer-term (>2 wk) to short-term
(2 wk) treatment in the involved (antibiotic treatment
> 2 wk, n ¼ 7 samples; antibiotic treatment  2 wk, n ¼ 5
samples) and uninvolved (antibiotic treatment >2 wk, n ¼
7 samples; antibiotic treatment  2 wk, n ¼ 4 samples)
regions. We observed neither a signiﬁcant difference in the
presence of Bacteroidetes or Clostridiales nor a clear
enrichment of aerobic organisms and depletion of anaer-
obic or microaerophilic organisms in the longer-term
treated group compared with short-term treatment (data
not shown). Because we did not have an untreated cohort
we could not determine reliably the consequences of
antibiotic treatment on the microbiome in this study.
However, Gevers et al6 previously investigated the inﬂu-
ence of antibiotic treatment for mucosal samples from CD  C
and uninvolved Crohn’s and IBD-free ileum segments. (B)
roidetes, Firmicutes, and Proteobacteria phyla. (C) Unsuper-
dance from 3 sample groups (red, involved; pink, uninvolved;
obability.
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between treated and untreated patients although the dys-
biosis was more pronounced in the treated group.
We next performed unsupervised hierarchical clustering
analysis based on genus-level bacterial abundance. Our re-
sults support the hypothesis that IBD-free ileum is signiﬁ-
cantly different than CD ileum, from both involved and
uninvolved regions (Figure 1B). There are few reports on the
microbiome of involved and uninvolved gut tissue in CD pa-
tients, although a study of colonic specimens has reported
differences in the CD-associated microbiota between these
regions.7
A metagenomic analysis of the 3 groups was performed
using the linear discriminant analysis effect size (LEfSe)
tool.8 Analysis of the microbial community diversity showed
that no phyla were enriched signiﬁcantly in involved vs un-
involved regions, although the genera Staphylococcus and
Delftia were increased modestly in inﬂamed regions using a
linear discriminant analysis (LDA) cut-off score of 3.0 or
greater (Figure 2A). At the species level resolution, we noted
a signiﬁcant enrichment (LDA score, 3.0) of Staphylococcus
aureus in involved (average relative abundance, 0.45%) vs
uninvolved tissue (average relative abundance, 0.05%).
Because LEfSe analysis does not perform multiple hypothe-
ses correction in identifying features signiﬁcantly enriched in
a group, we performed comparative marker selection using
GENE-E (available: http://www.broadinstitute.org/cancer/
software/GENE-E), to identify signiﬁcantly enriched fea-
tures in each group. Comparing involved (n ¼ 12) vs unin-
volved (n ¼ 11) regions conﬁrmed a marked but statistically
nonsigniﬁcant enrichment of S aureus in the involved sam-
ples with a false-discovery rate (FDR) of 0.19 (P ¼ .06) and a
fold increase of 7.76. Analysis of the S aureus sequencingInvolved
IB
InA B
Figure 2. Bacterial taxa in involved vs uninvolved regions of
vs IBD-free patients. (A) LDA and effect size measurements
genera in involved vs uninvolved ileal regions in Crohn’s patients
uninvolved tissues. Only taxa exceeding an LDA threshold of 3.0
of the most enriched taxa in involved ileum of Crohn’s patients v
green, taxa enriched in IBD-free tissues. LDA and effect size m
Supplementary Figure 2.reads showed the presence of an S aureus pathogenicity is-
land in the involved tissue from 2 patients (CD-I-82 and CD-I-
56). The S aureus pathogenicity islands are a large family of
mobile, phage-related, genetic elements, most of which carry
genes for 1 or more superantigens/enterotoxins.9 A recent
study reported infection with enterotoxigenic methicillin-
resistant S aureus in a Crohn’s patient with active colitis,
which was resolved after targeted antibiotic treatment.10
Superantigens secreted by these strains are potent T-cell
mitogens that lead to a massive release of proinﬂammatory
cytokines,11 and several reports have highlighted the ability
of enterotoxigenic strains to trigger intestinal inﬂamma-
tion.10,12–14 These observations suggest that enterotoxigenic
strains, coupled with compromised barrier function in in-
testinal epithelia, may contribute to localized lesions in CD.
We observed that the microbial community in the
involved ileum was markedly different from the IBD-free
ileum (Figure 2B and Supplementary Figure 2), including
enrichment of some Mycobacterium species in the involved
tissue. Mycobacterium species have been implicated previ-
ously in CD, speciﬁcally Mycobacterium avium.15 Here, we
observed an increase in Mycobacterium abscessus (average
relative abundance, 0.09% and 0.002% in involved and
normal tissue, respectively) (Supplementary Figures 2 and
3).16 Comparative marker selection with GENE-E conﬁrmed
the enrichment ofM abscessus in involved samples compared
with IBD-free samples, with a FDR of 0.044 (P ¼ .02) and a
fold increase of 53. Our results show a bacterial imbalance in
CD that is not restricted to mucosal surfaces, but also occurs
in the deeper intestinal layers. We showed a marked deple-
tion of Bacteroidetes in Crohn’s patients, regardless of the
presence of inﬂammation, which is consistent with studies
suggesting that depletion of commensals such asD-free
volved
Crohn’s patients, and involved regions of Crohn’s patients
identify a modest enrichment of Staphylococcus and Delftia
. Red, taxa enriched in involved regions; pink, taxa enriched in
(red dotted line) were considered for analysis. (B) A cladogram
s IBD-free individuals. Red, taxa enriched in involved regions;
easurements for involved segments vs IBD-free are shown in
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aberrant immune response.2 The Firmicutes phylum,
including the Bacilli class, is enriched with a LDA score of 3.0
or greater in involved regions compared with IBD-free ileum,
with enrichment of Streptococcus and Bacillus genera. We
observed depletion of the Clostridia class, speciﬁcally the
Clostridiales order, in involved ileum, which also is consistent
with the literature.6 An enrichment of potential bacterial
pathogens emerged at the species level, including S aureus
and M abscessus. Although this ﬁnding is intriguing and re-
fuels the debate on the role of Mycobacteria in CD, further
studies are required to conﬁrm or negate their role in CD.
Given that Mycobacterium species and S aureus are notori-
ously difﬁcult-to-lyse organisms,17–19 it is possible that we
may in fact be underestimating their abundance in these
samples. Moving forward, we intend to apply more effective
lysis methods to investigate their prevalence in CD more
rigorously. This approach may help reduce the intra-
individual variation in isolation of bacterial nucleic acids
from parafﬁn sections. Notably, our analysis of the deeper
diseased ileum did not show an enrichment of the bacterial
families Enterobacteriaceae, Pasteurellaceae, Veillonellaceae,
and Fusobacteriaceae previously observed in the upper
mucosal layers.6 Although members of these families, such as
Fusobacteria, have the potential to be invasive organisms, it
is possible that they are not invasive in CD and remain at the
mucosal interface. Interestingly, organisms belonging to the
bacterial families that Gevers et al6 noted as being enriched
in the mucosal layers, including obligate anaerobes (all
Veillonellaceae members and speciﬁc members of Fuso-
bacteriaceae), were absent in our analysis of the deeper ileal
layers. Rather, we observed aerobic (M abscessus) or aero-
tolerant (S aureus) species. A potential explanation for this is
that inﬂammation within the deeper layers can result in
increased oxygenated blood supply to these sites, promoting
the growth of these species. It is possible that oxygen tension
may determine which microbial species can colonize, and
ultimately contribute to, pathology.
In summary, the in situ microbial community of patients
with CD is distinct from IBD-free individuals. We show the
enrichment of an enterotoxigenic strain of S aureus in
diseased areas of the bowel as well as low levels of an
environmental mycobacterial species in CD. These microbial
communities may perpetuate stimulation of the host im-
mune response, contributing to the ileal Crohn’s phenotype
and necessitating surgical intervention. Our study had lim-
itations, including a smaller cohort size and the use of DNA
extraction methods from parafﬁn sections that are designed
for host, rather than microbial, cell lysis and nucleic acid
extraction. To deﬁne the contribution of the pathogens
identiﬁed in this study on the initiation and progression ofCrohn’s disease, further investigation is warranted with a
larger cohort size and optimized DNA extraction methods
for intracellular pathogens in conjunction with sophisticated
host nucleic acid–depletion approaches.
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Supplementary Materials and Methods
Sample Selection and Pathologic Review
All patient samples were selected using a clinically anno-
tated patient registry, (Prospective Registry in IBD Study at
Massachusetts General Hospital), in which more than 1000
patients are enrolled with detailed treatment history, IBD
genetics, and have consented to banking DNA, blood, and tis-
sue. Twenty-seven formalin-ﬁxed, parafﬁn-embedded ileal
resection samples were identiﬁed for further investigation.
The inclusion/exclusion criteria place an emphasis on select-
ing patientswith preferably less than 6months of exposure to
antibiotics and immunosuppressive agents, which could alter
the invasive gut microbiome. IBD-free ileum from right hem-
icolectomy specimens (obtained from colorectal carcinoma
surgeries) were selected as negative controls. Institutional
review board approval was obtained through the Massachu-
setts General Hospital and the Broad Institute. All patient
samples were de-identiﬁed. All samples were reviewed his-
tologically by a co-investigator who is a gastrointestinal
pathologist with a specialization in IBD (A.K.B.).
In pilot experiments, we selected 2 submucosal CD
samples, 2 deep ﬁssure macrodissected CD samples, 2
submucosal biopsy specimens from patients with appendi-
citis, and 1 Helicobacter pylori–positive gastric submucosal
sample (positive control sample) to validate our approach.
DNA Extraction, Library Construction,
and Sequencing
DNA was extracted from all formalin-ﬁxed, parafﬁn-
embedded samples using the Ambion Recoverall kit
(ThermoFisher Scientiﬁc, Waltham, MA), as previously
described.1 DNA was quantiﬁed using both a Nanodrop
apparatus and the Qubit quantiﬁcation system (Thermo-
Fisher Scientiﬁc). DNA was sheared using a Covaris appa-
ratus (Covaris, Woburn, MA) to an average fragment length
of 350–500 bp. Sequencing libraries were prepared using
the Illumina TruSeq kit per the manufacturer’s instructions
(Illumina, San Diego, CA). Samples were pooled and multi-
plexed before sequencing on the Illumina V3 HiSeq platform
(6 samples per lane, for an average depth of 3 human
whole genome sequencing coverage).
PathSeq and Statistical Analysis
The PathSeq2 algorithm was used to perform computa-
tional subtraction of human reads, followed by alignments
of residual reads to human reference genomes and micro-
bial reference genomes (which included bacterial, viral,
archaeal, and fungal sequences; downloaded from National
Center for Biotechnology Information in June, 2012). These
alignments resulted in taxonomic classiﬁcation of reads into
bacterial, viral, archaeal, and fungal sequences in whole
genome sequencing data.
Brieﬂy, PathSeq is used to remove low-quality reads
followed by subtraction of human reads by mapping reads
to a database of human genomes (downloaded from NCBI in
November 2011) using BWA3 (release 0.6.1, default set-
tings), MegaBLAST (release 2.2.25; cut-off E-value, 10-7;
word size, 16), and BLASTN4 (release 2.2.25; cut-off
E-value, 10-7; word size, 7; nucleotide match reward, 1;
nucleotide mismatch score, -3; gap open cost, 5; and gap
extension cost, 2). Only sequences with perfect or near-
perfect matches to the human genome were removed in
the subtraction process. In addition, low-complexity and
highly repetitive reads were removed using Repeat Masker5
(version open-3.3.0; libraries dated 2011-04-19).
Taxonomic classiﬁcation is performed by residual read
alignment using MegaBLAST (release 2.2.25; cut-off E-value,
10-7; word size, 16) to a database of bacterial sequences and
followed by BLASTN (release 2.2.25; cut-off E-value, 10-7;
word size, 7) to human reference gnome and microbial
reference genomes.
After the taxonomic classiﬁcation of nonhuman DNA
sequencing reads the relative abundance value for each
bacterial organism was calculated as follows by using reads
that maps with 90% or greater sequence identity and 90%
or greater query coverage. Classiﬁcations were performed
at the domain, then phylum, then genus, and then species
level, requiring unique alignments (ie, reads with equivalent
E-values to multiple taxa were removed from analysis).
At the species level, relative abundance for each organ-
ism was calculated as follows: relative abundance ¼
(number of unique alignment positions in genome 
1,000,000)/(number of total aligned bacterial reads 
genome size). The relative abundance values then were per-
sample normalized such that the total relative abundance
for each sample summed to 1. The resulting normalized
relative abundance matrix was analyzed on LEfSe (online
version available on August 2015)6 between different
sample group labels (uninvolved, involved, and IBD-free
samples) with default parameters. However, we consid-
ered the bacteria that had a LDA score of 3.0 or greater for
further analysis. In addition, the Wilcoxon rank-sum test
was used to calculate the P value for phyla level relative
abundance between groups. Unsupervised hierarchi-
cal clustering was performed using the pvclust R package
(available: https://cran.r-project.org/web/packages/
pvclust/index.html) with 1000 bootstrap iterations,
Ward’s clustering method, and otherwise default parame-
ters on genus level bacterial relative abundance values.
Comparative marker selection was used to complement
LEfSe analysis via GENE-E (http://www.broadinstitute.org/
cancer/software/GENE-E/) with default settings and
10,000 permutations. This analysis was performed between
involved (n ¼ 12) and uninvolved (n ¼ 11) samples, and
between involved (n ¼ 12) and IBD-free (n ¼ 12) samples.
This analysis returned a FDR, a fold change, and a P value
based on a permutation test.
Results of Sequencing and PathSeq Analysis
PathSeq was used to assign a taxonomic classiﬁcation of
each sequence based on the organism of origin. Results
from pilot experiments (complete data not shown) used to
validate our approach shows accurate identiﬁcation of H
pylori in H pylori–positive gastric submucosal samples
(Supplementary Figure 1A). We obtained a median of 39.3
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million human DNA sequencing reads (range, 14.5–188.8
million), 2330 bacterial sequencing reads (range,
244–19445 reads), and 8660 unmapped sequencing reads
(range, 2110–78466 reads) per Crohn’s disease or IBD-free
sample. Microbial reads included those corresponding to
known bacteria, archaea, fungi, and viruses. The number of
human reads, microbial reads, and unmapped reads are
presented in Supplementary Table 2. The relative abun-
dance for each bacterium at the species level is presented in
Supplementary Table 4.
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Supplementary Figure 1. H&E sections of small intestine showing (A) relative abundance levels of various Helicobacter
species in pilot set. Results show accurate identiﬁcation of H pylori in a H pylori–positive gastric submucosal sample. (B and
C) Representative H&E section before and after macrodissection of diseased area of the small bowel is shown. (B) The
sequenced portion of the bowel wall is shown as a circle and was removed from the parafﬁn section by the biopsy needle. (C)
The rest of the bowel wall otherwise is intact.
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Supplementary Figure 2. LDA coupled with effect size
measurements identiﬁes signiﬁcant depletion of Bacter-
oidetes phyla and Clostridia class in Firmicutes phyla
when compared with involved ileum segments with IBD-
free ileum. In addition, there was signiﬁcant enrichment of
Bacilli class in Firmicutes phyla when comparing involved
ileum segments with IBD-free. Involved enriched taxon have a
negative score (red), and taxa enriched in IBD-free tissue have
a positive score (green). Only taxameeting an LDA threshold of
3.0 (red dotted line) were considered for analysis.
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Supplementary Figure 3. Relative abundance of various Mycobacterium species in the cohort.
Supplementary Figure 4. Box plots show comparison of Bacteroidetes, Firmicutes, and Proteobacteria phyla between
our study and the Gevers et al7 study.
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